Aerie Pharmaceuticals, Inc.
Symboli: AERI
NASDAQ
15.25
USDMarkkinahinta tänään
-9.4457
P/E-suhde
0.2147
PEG-suhde
753.62M
MRK Cap
- 0.00%
DIV Tuotto
Aerie Pharmaceuticals, Inc. (AERI) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 691.88 | 139.8 | 240.4 | 309.2 | |||||||||||
balance-sheet.row.short-term-investments | 504.72 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.net-receivables | 364.41 | 158.8 | 56 | 38.4 | |||||||||||
balance-sheet.row.inventory | 174.37 | 40.4 | 27.1 | 21.1 | |||||||||||
balance-sheet.row.other-current-assets | 56.18 | 16.6 | 8.3 | 7.7 | |||||||||||
balance-sheet.row.total-current-assets | 1286.84 | 355.6 | 331.8 | 376.3 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 290.73 | 74.1 | 68.3 | 58.1 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 3.98 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 6.32 | 1.6 | 1.9 | 18.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 301.03 | 75.7 | 70.3 | 76.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.account-payables | 34.5 | 8.3 | 8.8 | 12.8 | |||||||||||
balance-sheet.row.short-term-debt | 18.45 | 4.4 | 4.9 | 5.5 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 1253.65 | 256.3 | 210.4 | 188.7 | |||||||||||
Deferred Revenue Non Current | 275.63 | 64.3 | 50.9 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 164.69 | 48 | 39.9 | 65.4 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 1542.75 | 323.7 | 273.6 | 202 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 101.17 | 26.1 | 15.1 | 17.6 | |||||||||||
balance-sheet.row.total-liab | 2036.03 | 448.7 | 378.1 | 285.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.19 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -4645 | -1153.9 | -1079.1 | -896 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.15 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 4198.8 | 1136.7 | 1103.1 | 1063 | |||||||||||
balance-sheet.row.total-stockholders-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1587.87 | - | - | - | |||||||||||
Total Investments | 508.71 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.total-debt | 1272.1 | 260.6 | 215.3 | 194.2 | |||||||||||
balance-sheet.row.net-debt | 1084.93 | 223.5 | 63.7 | 50.2 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 18.4 | 29.5 | 40.1 | 45.1 | |||||||||||
cash-flows.row.change-in-working-capital | 5.69 | -92.6 | 44.9 | -24 | |||||||||||
cash-flows.row.account-receivables | -9.31 | -12.8 | -17.7 | -35.6 | |||||||||||
cash-flows.row.inventory | -15.16 | -12.1 | -5.2 | -10.3 | |||||||||||
cash-flows.row.account-payables | -7.51 | 21.6 | 16.9 | -270.8 | |||||||||||
cash-flows.row.other-working-capital | 37.68 | -89.2 | 50.9 | 292.7 | |||||||||||
cash-flows.row.other-non-cash-items | -0.53 | 1.2 | -0.7 | 9.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.17 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -165.66 | -132.4 | -116.6 | -165.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 151.88 | 117.5 | 192.9 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -7.8 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -18.3 | -18.2 | 73.2 | -183.2 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -8.3 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 2.42 | 3 | -0.9 | 0.7 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.96 | 0 | 8.3 | 274.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 3.38 | 3 | -0.9 | 274.8 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -7.75 | -114.4 | 7.6 | -58.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 187.16 | 37.2 | 151.6 | 143.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 194.92 | 151.6 | 143.9 | 202.8 | |||||||||||
cash-flows.row.operating-cash-flow | 7.17 | -99.2 | -64.7 | -150.4 | |||||||||||
cash-flows.row.capital-expenditure | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.free-cash-flow | 2.64 | -102.4 | -67.8 | -160.4 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 213.94 | 194.1 | 83.1 | 69.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 23.52 | 26.8 | 25.3 | 4.8 | |||||||||||
income-statement-row.row.gross-profit | 190.42 | 167.3 | 57.8 | 65.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 87.57 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.operating-expenses | 217.13 | 213.6 | 213.5 | 252.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 240.65 | 240.5 | 238.8 | 257.4 | |||||||||||
income-statement-row.row.interest-income | 0.88 | 0.1 | 2 | 3 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
income-statement-row.row.ebitda-caps | -3.07 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -23.24 | -45.3 | -155.7 | -187.5 | |||||||||||
income-statement-row.row.income-before-tax | -35.23 | -74.2 | -177.9 | -199.7 | |||||||||||
income-statement-row.row.income-tax-expense | 1.32 | 0.6 | 5.2 | -0.1 | |||||||||||
income-statement-row.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 |
Usein kysytty kysymys
Mikä on Aerie Pharmaceuticals, Inc. (AERI) taseen loppusumma?
Aerie Pharmaceuticals, Inc. (AERI) kokonaisvarat ovat 431391000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 69440000.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.862.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -2.211.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -0.385.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.233.
Mikä on Aerie Pharmaceuticals, Inc. (AERI) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -74810000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 260643000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 213642000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 54093000.000.